Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : AXSM source : Www.biospace.com save search
Cybin Announces Unprecedented Positive Phase 2 Interim Data for CYB003 in Major Depressive Disorder Meeting Primary Efficacy Endpoint with Rapid and Significant Improvements in Depression Symptoms After Single Dose
Published: 2023-10-31 (Crawled : 23:00) - biospace.com/
CYBN | $0.3677 -0.6% 0.35% 1.8M
|
n/a
|
| O: 11.35%
H: 9.32%
C: -4.16%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.33%
H: 0.0%
C: 0.0%
AXSM | $67.91 3.33% 3.22% 890K
|
Health Technology
|
| O: 0.0%
H: 3.76%
C: 3.75%
cyb003 rapid positive depression meeting
Axsome Therapeutics to Report Second Quarter 2023 Financial Results on August 7Axsome to host conference call and webcast on Monday, Aug. 7, 2023, at 8:00 a.m. Eastern Time
Published: 2023-07-12 (Crawled : 13:00) - biospace.com/
AXSM | $67.91 3.33% 3.22% 890K
|
Health Technology
|
| O: 1.0%
H: 0.0%
C: -0.66%
conference report therapeutics financial results
Axsome Therapeutics Announces Proposed Public Offering of Common Stock - June 28, 2023
Published: 2023-06-28 (Crawled : 08:00) - biospace.com/
AXSM | $67.91 3.33% 3.22% 890K
|
Health Technology
|
| O: -10.04%
H: 1.2%
C: -0.03%
offering therapeutics
Axsome Therapeutics Joins Mental Health America and the State of New York to Raise Awareness of Mental Health During May is Mental Health Month
Published: 2023-05-01 (Crawled : 13:20) - biospace.com/
AXSM | $67.91 3.33% 3.22% 890K
|
Health Technology
|
| O: 0.22%
H: 1.86%
C: -1.28%
america health state therapeutics
Axsome Therapeutics to Present Five Abstracts Including New Data from the Positive SHARP Study of SUNOSI® (solriamfetol)
Published: 2023-04-21 (Crawled : 12:00) - biospace.com/
AXSM | $67.91 3.33% 3.22% 890K
|
Health Technology
|
| O: 0.49%
H: 6.57%
C: 1.79%
sunosi positive therapeutics study
Axsome Therapeutics to Report First Quarter 2023 Financial Results on May 8Axsome to host conference call and webcast on Monday, May 8, 2023, at 8:00 a.m. Eastern Time
Published: 2023-04-13 (Crawled : 12:20) - biospace.com/
AXSM | $67.91 3.33% 3.22% 890K
|
Health Technology
|
| O: 0.49%
H: 3.94%
C: 1.72%
conference report therapeutics financial results
Axsome Therapeutics to Present at Cowen’s 43rd Annual Health Care Conference
Published: 2023-03-01 (Crawled : 14:00) - biospace.com/
AXSM | $67.91 3.33% 3.22% 890K
|
Health Technology
|
| O: -0.51%
H: 4.29%
C: -1.4%
care conference health therapeutics
Axsome Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Published: 2023-02-27 (Crawled : 14:00) - biospace.com/
AXSM | $67.91 3.33% 3.22% 890K
|
Health Technology
|
| O: 4.83%
H: 3.09%
C: 0.13%
year therapeutics financial update results
Axsome Therapeutics Enters into License Agreement with Pharmanovia to Expand Commercialization and Further Develop Sunosi® (solriamfetol) in Europe
Published: 2023-02-22 (Crawled : 13:00) - biospace.com/
MS | News 0 d | $90.66 0.44% 0.07% 8.1M
|
Finance
|
| O: -0.26%
H: 0.72%
C: -0.1%
AXSM | $67.91 3.33% 3.22% 890K
|
Health Technology
|
| O: 1.21%
H: 1.23%
C: -2.52%
sunosi europe commercialization license therapeutics agreement solriamfetol
Axsome Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on February 27Axsome to host conference call and webcast on Monday, Feb. 27, 2023, at 8:00 a.m. ET
Published: 2023-01-31 (Crawled : 13:00) - biospace.com/
AXSM | $67.91 3.33% 3.22% 890K
|
Health Technology
|
| O: 0.0%
H: 3.64%
C: 2.31%
conference report year therapeutics financial results
Axsome Therapeutics Presents New Data from the EVOLVE Open-Label Trial Demonstrating Effects of AUVELITY® on Cognitive and Physical Functioning in Patients with Major Depressive Disorder
Published: 2022-12-07 (Crawled : 13:00) - biospace.com/
AXSM | $67.91 3.33% 3.22% 890K
|
Health Technology
|
| O: 0.32%
H: 4.77%
C: 3.52%
auvelity trial therapeutics major depressive disorder
Axsome Therapeutics to Present at the 5th Annual Evercore ISI HealthCONx Conference
Published: 2022-11-23 (Crawled : 13:00) - biospace.com/
AXSM | $67.91 3.33% 3.22% 890K
|
Health Technology
|
| O: 0.93%
H: 0.48%
C: -2.67%
conference therapeutics
Axsome Therapeutics to Present at the Guggenheim 4th Annual Immunology and Neurology Conference
Published: 2022-11-09 (Crawled : 13:00) - biospace.com/
AXSM | $67.91 3.33% 3.22% 890K
|
Health Technology
|
| O: 0.24%
H: 3.99%
C: -7.22%
conference immunology therapeutics
Axsome Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
Published: 2022-11-07 (Crawled : 13:00) - biospace.com/
AXSM | $67.91 3.33% 3.22% 890K
|
Health Technology
|
| O: -4.94%
H: 8.4%
C: 4.7%
therapeutics financial update results
Axsome Therapeutics to Report Third Quarter 2022 Financial Results on November 7, 2022
Published: 2022-10-21 (Crawled : 12:00) - biospace.com/
AXSM | $67.91 3.33% 3.22% 890K
|
Health Technology
|
| O: -0.09%
H: 1.15%
C: -6.09%
report therapeutics financial results
Axsome Therapeutics Announces Availability of AUVELITY™, the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults
Published: 2022-10-20 (Crawled : 12:00) - biospace.com/
AXSM | $67.91 3.33% 3.22% 890K
|
Health Technology
|
| O: -0.71%
H: 2.82%
C: -1.14%
treatment therapeutics major depressive disorder
Axsome Therapeutics Voices its Commitment to Mental Health on World Mental Health Day 2022
Published: 2022-10-10 (Crawled : 12:00) - biospace.com/
AXSM | $67.91 3.33% 3.22% 890K
|
Health Technology
|
| O: -0.92%
H: 0.0%
C: -3.44%
day health therapeutics
Axsome Therapeutics Announces Sunosi® (Solriamfetol) Meets Primary Endpoint Demonstrating Improvement in Cognitive Function in the SHARP Trial
Published: 2022-10-03 (Crawled : 12:00) - biospace.com/
AXSM | $67.91 3.33% 3.22% 890K
|
Health Technology
|
| O: 2.08%
H: 1.19%
C: -0.48%
sunosi trial therapeutics solriamfetol
Axsome Therapeutics Announces Plans to Resubmit AXS-07 NDA Based on Successful FDA Type A Meeting
Published: 2022-09-29 (Crawled : 12:20) - biospace.com/
AXSM | $67.91 3.33% 3.22% 890K
|
Health Technology
|
| O: 0.71%
H: 1.26%
C: -6.06%
axs-07 fda meeting therapeutics
Axsome Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022
Published: 2022-07-28 (Crawled : 14:20) - biospace.com/
AXSM | $67.91 3.33% 3.22% 890K
|
Health Technology
|
| O: 1.38%
H: 0.64%
C: -1.28%
report therapeutics results
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.